371 related articles for article (PubMed ID: 29795041)
61. BRAF Inhibitors for BRAF V600E Mutant Colorectal Cancers: Literature Survey and Case Report.
Peker YS; Can MF; Ozerhan IH; Yagci G; Zeybek N; Kavakli K; Gurkok S; Gozubuyuk A; Genc O; Erdem G; Ozet A; Gerek M; Peker Y
Case Rep Surg; 2018; 2018():8782328. PubMed ID: 29850361
[TBL] [Abstract][Full Text] [Related]
62. A phase II study of combined therapy with a BRAF inhibitor (vemurafenib) and interleukin-2 (aldesleukin) in patients with metastatic melanoma.
Mooradian MJ; Reuben A; Prieto PA; Hazar-Rethinam M; Frederick DT; Nadres B; Piris A; Juneja V; Cooper ZA; Sharpe AH; Corcoran RB; Flaherty KT; Lawrence DP; Wargo JA; Sullivan RJ
Oncoimmunology; 2018; 7(5):e1423172. PubMed ID: 29721378
[No Abstract] [Full Text] [Related]
63. Aberrant apoptotic machinery confers melanoma dual resistance to BRAF(V600E) inhibitor and immune effector cells: immunosensitization by a histone deacetylase inhibitor.
Jazirehi AR; Nazarian R; Torres-Collado AX; Economou JS
Am J Clin Exp Immunol; 2014; 3(1):43-56. PubMed ID: 24660121
[TBL] [Abstract][Full Text] [Related]
64. Vemurafenib enhances MHC induction in BRAF
Sapkota B; Hill CE; Pollack BP
Oncoimmunology; 2013 Jan; 2(1):e22890. PubMed ID: 23483066
[TBL] [Abstract][Full Text] [Related]
65. Novel mechanisms of resistance to vemurafenib in melanoma - V600E B-Raf reversion and switching VEGF-A splice isoform expression.
Beazley-Long N; Gaston K; Harper SJ; Orlando A; Bates DO
Am J Cancer Res; 2015; 5(1):433-41. PubMed ID: 25628951
[TBL] [Abstract][Full Text] [Related]
66. Melanoma patient derived xenografts acquire distinct Vemurafenib resistance mechanisms.
Monsma DJ; Cherba DM; Eugster EE; Dylewski DL; Davidson PT; Peterson CA; Borgman AS; Winn ME; Dykema KJ; Webb CP; MacKeigan JP; Duesbery NS; Nickoloff BJ; Monks NR
Am J Cancer Res; 2015; 5(4):1507-18. PubMed ID: 26101714
[TBL] [Abstract][Full Text] [Related]
67. Histone Deacetylase Inhibitors to Overcome Resistance to Targeted and Immuno Therapy in Metastatic Melanoma.
Yeon M; Kim Y; Jung HS; Jeoung D
Front Cell Dev Biol; 2020; 8():486. PubMed ID: 32626712
[TBL] [Abstract][Full Text] [Related]
68. Cutaneous Side Effects of BRAF Inhibitors in Advanced Melanoma: Review of the Literature.
Gençler B; Gönül M
Dermatol Res Pract; 2016; 2016():5361569. PubMed ID: 27042173
[TBL] [Abstract][Full Text] [Related]
69. Bioenergetic modulation with the mitochondria uncouplers SR4 and niclosamide prevents proliferation and growth of treatment-naïve and vemurafenib-resistant melanomas.
Figarola JL; Singhal J; Singhal S; Kusari J; Riggs A
Oncotarget; 2018 Dec; 9(97):36945-36965. PubMed ID: 30651927
[TBL] [Abstract][Full Text] [Related]
70. A Novel Aptamer LL4A Specifically Targets Vemurafenib-Resistant Melanoma through Binding to the CD63 Protein.
Li H; Liu J; Xiao X; Sun S; Zhang H; Zhang Y; Zhou W; Zhang B; Roy M; Liu H; Ye M; Wang Z; Liu-Smith F; Liu J
Mol Ther Nucleic Acids; 2019 Dec; 18():727-738. PubMed ID: 31726389
[TBL] [Abstract][Full Text] [Related]
71. Bilirubin Restrains the Anticancer Effect of Vemurafenib on BRAF-Mutant Melanoma Cells Through ERK-MNK1 Signaling.
Tan Y; Zhong X; Wen X; Yao L; Shao Z; Sun W; Wu J; Wen G; Tang D; Zhang X; Liao Y; Liu J
Front Oncol; 2021; 11():698888. PubMed ID: 34222023
[TBL] [Abstract][Full Text] [Related]
72. BRAF in malignant melanoma progression and metastasis: potentials and challenges.
Alqathama A
Am J Cancer Res; 2020; 10(4):1103-1114. PubMed ID: 32368388
[TBL] [Abstract][Full Text] [Related]
73. The Downregulation of eIF3a Contributes to Vemurafenib Resistance in Melanoma by Activating ERK via PPP2R1B.
Jiang SL; Wang ZB; Zhu T; Jiang T; Fei JF; Liu C; Luo C; Cheng Y; Liu ZQ
Front Pharmacol; 2021; 12():720619. PubMed ID: 34512348
[TBL] [Abstract][Full Text] [Related]
74. RSK2 promotes melanoma cell proliferation and vemurafenib resistance
Wu HZ; Li LY; Jiang SL; Li YZ; Shi XM; Sun XY; Li Z; Cheng Y
Front Pharmacol; 2022; 13():950571. PubMed ID: 36210843
[TBL] [Abstract][Full Text] [Related]
75. Vemurafenib Combined With Trametinib Significantly Benefits the Survival of a Patient With Stage IV Pancreatic Ductal Adenocarcinoma With BRAF V600E Mutation: A Case Report.
Wang Z; He D; Chen C; Liu X; Ke N
Front Oncol; 2021; 11():801320. PubMed ID: 35145907
[TBL] [Abstract][Full Text] [Related]
76. Selective BRAF inhibition decreases tumor-resident lymphocyte frequencies in a mouse model of human melanoma.
Hooijkaas A; Gadiot J; Morrow M; Stewart R; Schumacher T; Blank CU
Oncoimmunology; 2012 Aug; 1(5):609-617. PubMed ID: 22934253
[TBL] [Abstract][Full Text] [Related]
77. Sudden Onset of Brain Metastasis despite the Use of Vemurafenib for Another Metastatic Lesion in Malignant Melanoma Patients.
Imafuku K; Yoshino K; Yamaguchi K; Tsuboi S; Ohara K; Hata H
Case Rep Oncol; 2017; 10(1):290-295. PubMed ID: 28512412
[TBL] [Abstract][Full Text] [Related]
78. The Tubulin Inhibitor VERU-111 in Combination With Vemurafenib Provides an Effective Treatment of Vemurafenib-Resistant A375 Melanoma.
Cui H; Wang Q; Miller DD; Li W
Front Pharmacol; 2021; 12():637098. PubMed ID: 33841154
[TBL] [Abstract][Full Text] [Related]
79.
Del Bufalo F; Ceglie G; Cacchione A; Alessi I; Colafati GS; Carai A; Diomedi-Camassei F; De Billy E; Agolini E; Mastronuzzi A; Locatelli F
Front Oncol; 2018; 8():526. PubMed ID: 30488019
[TBL] [Abstract][Full Text] [Related]
80. Glucocorticoid receptor antagonism overcomes resistance to BRAF inhibition in BRAF
Estrela JM; Salvador R; Marchio P; Valles SL; López-Blanch R; Rivera P; Benlloch M; Alcácer J; Pérez CL; Pellicer JA; Obrador E
Am J Cancer Res; 2019; 9(12):2580-2598. PubMed ID: 31911848
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
